Nitrofurantoin is the preferred primary therapy for uncomplicated UTI with these susceptibility results
For an uncomplicated urinary tract infection with both agents showing susceptibility (cefazolin MIC ≤1.0 µg/mL and nitrofurantoin MIC ≤16 µg/mL), nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days should be selected as first-line treatment.
Rationale Based on Guidelines
The most recent and authoritative guidelines consistently prioritize nitrofurantoin as first-line therapy for uncomplicated cystitis. The 2011 IDSA/ESMID guidelines 1 and the 2024 EAU guidelines 2 both recommend nitrofurantoin as a primary agent, while the 2025 AUA/CUA/SUFU guidelines 3 reaffirm this position with updated evidence.
Why Nitrofurantoin Over Cefazolin
Nitrofurantoin demonstrates:
- Clinical efficacy of 88-93% with bacterial cure rates of 86-92% 1
- Minimal collateral damage to gut and other microbiota 1, 3
- Stable, low resistance rates maintained over 50 years 3
- Narrow antimicrobial spectrum targeting primarily E. coli and S. saprophyticus 3
Beta-lactams (including cefazolin/cephalexin) are explicitly designated as second-line agents in the IDSA guidelines 1. The guidelines state that β-lactams "generally have inferior efficacy and more adverse effects, compared with other UTI antimicrobials" and recommend they "should be used with caution for uncomplicated cystitis" 1.
Specific Efficacy Comparison
While both agents show susceptibility in your case, the clinical trial data reveals important differences:
- Nitrofurantoin: 93% clinical cure rate, 88% microbiological cure rate 1
- Beta-lactams (including cephalosporins): 89% clinical cure rate, 82% microbiological cure rate 1
The 4-6% difference in microbiological cure rates is clinically meaningful for preventing recurrence.
Antimicrobial Stewardship Considerations
Cefazolin and oral cephalosporins should be reserved for situations where nitrofurantoin cannot be used because:
- Broader spectrum activity increases selection pressure for resistant organisms
- Greater collateral damage to commensal flora increases risk of C. difficile and other opportunistic infections
- Contributes to beta-lactam resistance in community uropathogens
Recent research 4 specifically highlights that despite cefazolin showing 87.9% susceptibility in ED populations, nitrofurantoin (88.1%) remains the preferred agent due to stewardship principles.
When to Choose Cefazolin Instead
Use oral cephalosporins (cephalexin, not IV cefazolin) only when:
- Patient has contraindications to nitrofurantoin (CrCl <30 mL/min, pregnancy at term, G6PD deficiency)
- Documented nitrofurantoin allergy or intolerance
- Suspected upper tract involvement (pyelonephritis) where nitrofurantoin has inadequate tissue penetration
- Patient cannot tolerate 5-day course and requires alternative
Dosing Specifications
Nitrofurantoin monohydrate/macrocrystals:
- 100 mg orally twice daily for 5 days 1, 3, 2
- Take with food to enhance absorption and reduce GI side effects
- Expected adverse effects: nausea, headache (28% incidence) 1
If cephalexin must be used (not IV cefazolin):
Critical Pitfalls to Avoid
- Do not use IV cefazolin for outpatient uncomplicated cystitis - the FDA labeling 5 indicates cefazolin is for IV/IM use in systemic infections, not oral treatment of simple cystitis
- Do not assume equal efficacy - susceptibility testing at neutral pH may underestimate nitrofurantoin's in vivo performance in acidic urine 6
- Do not prescribe fluoroquinolones - these should be reserved for pyelonephritis or complicated infections 1
- Avoid treating asymptomatic bacteriuria - even with positive cultures, treatment without symptoms causes harm 3
The evidence overwhelmingly supports nitrofurantoin as the optimal choice when both agents are susceptible, based on efficacy, safety profile, resistance patterns, and antimicrobial stewardship principles 1, 3, 2, 7.